Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

I Roos; C Malpas; E Leray; R Casey; D Horakova; EK Havrdova; M Debouverie; F Patti; J De Seze; G Izquierdo; S Eichau; G Edan; A Prat; M Girard; S Ozakbas; P Grammond; H Zephir; J Ciron; E Maillart; T Moreau; MP Amato; P Labauge; R Alroughani; K Buzzard; O Skibina; M Terzi; DA Laplaud; E Berger; F Grand'maison; C Lebrun-Frenay; E Cartechini; C Boz; J Lechner-Scott; P Clavelou; B Stankoff; J Prevost; L Kappos; J Pelletier; V Shaygannejad; BI Yamout; SJ Khoury; O Gerlach; DLA Spitaleri; V Van Pesch; O Gout; R Turkoglu; O Heinzlef; E Thouvenot; PA McCombe; A Soysal; B Bourre; M Slee; T Castillo-Trivino; S Bakchine; R Ampapa; EG Butler; A Wahab; RA MacDonell; E Aguera-Morales; P Cabre; NH Ben; A Van Der Walt; G Laureys; L Van Hijfte; CM Ramo-Tello; N Maubeuge; S Hodgkinson; JL Sánchez-Menoyo; MH Barnett; C Labeyrie; S Vucic; Y Sidhom; R Gouider; T Csepany; J Sotoca; K De Gans; A Al-Asmi; YD Fragoso; S Vukusic; H Butzkueven; T Kalincik

Journal article

Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

I Roos, C Malpas, E Leray, R Casey, D Horakova, EK Havrdova, M Debouverie, F Patti, J De Seze, G Izquierdo, S Eichau, G Edan, A Prat, M Girard, S Ozakbas, P Grammond, H Zephir, J Ciron, E Maillart, T Moreau Show all

Neurology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2022

DOI: 10.1212/WNL.0000000000201029

Abstract

Background and ObjectivesTo evaluate the rate of return of disease activity after cessation of multiple sclerosis (MS) disease-modifying therapy.MethodsThis was a retrospective cohort study from 2 large observational MS registries: MSBase and OFSEP. Patients with relapsing-remitting MS who had ceased a disease-modifying therapy and were followed up for the subsequent 12 months were included in the analysis. The primary study outcome was annualized relapse rate in the 12 months after disease-modifying therapy discontinuation stratified by patients who did, and did not, commence a subsequent therapy. The secondary endpoint was the predictors of first relapse and disability accumulation after t..

View full abstract

University of Melbourne Researchers

Izanne Roos Author

Charles Malpas Author

Richard MacDonell Author

Tomas Kalincik Author

Related Projects (3)

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

BIOMARKERS TO PREVENT DISABILITY IN MULTIPLE SCLEROSIS

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

This study was supported by the EDMUS Foundation and NHMRC (1140766, 1129189, and 1157717). I. Roos is supported by a MSIF-ARSEP McDonald Fellowship, Biogen project grant, and a Melbourne Research Scholarship. The MSBase Foundation is a not-for-profit organization that receives support from Biogen, Novartis, Merck, Roche, Teva, and Sanofi Genzyme. The Observatoire Francais de la Sclerose en Plaques (OFSEP) is supported by a grant provided by the French State and handled by the "Agence Nationale de la Recherche," within the framework of the "Investments for the Future" program, under the reference ANR-10-COHO-002, by the Eugene Devic EDMUS Foundation against MS and by the ARSEP Foundation. This study was conducted separately and apart from the guidance of the sponsors.